Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients

[1] Meštrović-Štefekov J(2018)Psychological stress in patients with atopic dermatitis Acta Dermatovenerol Croat 26 297-303

[2] Novak-Bilić G(2020)Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2 J Dermatolog Treat 31 606-14

[3] Kuna M(2019)Impact of acute stress on itch sensation and scratching behaviour in patients with atopic dermatitis and healthy controls Br J Dermatol 180 821-7

[4] Pap N(2014)Dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis N Engl J Med 371 130-9

[5] Lugović-Mihić L(2016)Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD) J Am Acad Dermatol 75 506-15

[6] Cork MJ(2007)What are the best outcome measurements for atopic eczema? A systematic review J Allergy Clin Immunol 120 1389-98

[7] Eckert L(1994)Dermatology Life Quality Index (DLQI)—α simple practical measure for routine clinical use Clin Exp Dermatol 19 210-6

[8] Simpson EL(2016)Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) Br J Dermatol 175 69-79

[9] Mochizuki H(2019)Consensus statement on the psychological needs of patients with chronic inflammatory skin diseases Actas Dermosifiliogr 110 102-14

[10] Lavery MJ(2013)Subiektywna ocena objawów i efektów leczenia a natezenie stresu i poziomu leku wśród pacjentów z wybranymi chorobami skóry i uktadu pokarmowego [Subjective evaluation of symptoms and effects of treatment and the intensity of the stress and anxiety levels among patients with selected diseases of the skin and gastrointestinal tract] Psychiatr Pol 47 225-37

[1] Meštrović-Štefekov J(2018)Psychological stress in patients with atopic dermatitis Acta Dermatovenerol Croat 26 297-303

[2] Novak-Bilić G(2020)Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2 J Dermatolog Treat 31 606-14

[3] Kuna M(2019)Impact of acute stress on itch sensation and scratching behaviour in patients with atopic dermatitis and healthy controls Br J Dermatol 180 821-7

[4] Pap N(2014)Dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis N Engl J Med 371 130-9

[5] Lugović-Mihić L(2016)Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD) J Am Acad Dermatol 75 506-15

[6] Cork MJ(2007)What are the best outcome measurements for atopic eczema? A systematic review J Allergy Clin Immunol 120 1389-98

[7] Eckert L(1994)Dermatology Life Quality Index (DLQI)—α simple practical measure for routine clinical use Clin Exp Dermatol 19 210-6

[8] Simpson EL(2016)Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) Br J Dermatol 175 69-79

[9] Mochizuki H(2019)Consensus statement on the psychological needs of patients with chronic inflammatory skin diseases Actas Dermosifiliogr 110 102-14

[10] Lavery MJ(2013)Subiektywna ocena objawów i efektów leczenia a natezenie stresu i poziomu leku wśród pacjentów z wybranymi chorobami skóry i uktadu pokarmowego [Subjective evaluation of symptoms and effects of treatment and the intensity of the stress and anxiety levels among patients with selected diseases of the skin and gastrointestinal tract] Psychiatr Pol 47 225-37